- About the OncoArray Network
- OncoArray Network Membership
- OncoArray Network Steering Committee
The overall goal of the OncoArray Network is to gain new insight into the genetic architecture and mechanisms underlying breast, ovarian, prostate, colorectal, and lung cancers. The Network's major aim is to discover new cancer susceptibility variants. In addition, through fine mapping and high-density genotyping, this project offers an unprecedented opportunity to determine variants in known loci and to identify new – and rarer – variants.
About the OncoArray Network
The Network was formed to develop and genotype a new custom genotyping array (the "OncoArray"). The OncoArray Network brings together multiple disease-based consortia.
The OncoArray Network has assembled more than 400,000 samples from existing studies and several biobanks. The OncoArray, which includes approximately 570K single nucleotide polymorphism (SNP) markers, is a custom array being manufactured by Illumina. Genotyping began in October 2013. The array includes a backbone of approximately 260,000 SNPs that provide genome-wide coverage of most common variants, together with markers of interest for each of the five diseases identified through genome-wide association studies (GWAS), fine-mapping of known susceptibility regions, sequencing studies, and other approaches. The array also includes loci of interest identified through studies of other cancer types, and other loci of interest to multiple cancer types (including loci associated with cancer related phenotypes, drug metabolism and radiation response). Additionally, SNPs relating to quantitative phenotypes such as body mass index (BMI), height, and breast density that correlate with common cancer risks are also included.
The OncoArray Network is funded through substantial grants from the NCI through the Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative and the Division of Cancer Epidemiology and Genetics (DCEG), Genome Canada/Génome Québec/Canadian Institutes of Health Research (CIHR) through the Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer international project, Cancer Research UK (University of Cambridge), and a grant from the European Union's Seventh Framework Programme for Research (FP7) for the Collaborative Oncological Gene-environment Study (COGS), together with many other smaller grants.
OncoArray Network Membership
Current members of the OncoArray Network include:
- GAME-ON Initiative Consortia
- ColoRectal Transdisciplinary Study (CORECT)
- Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE)
- Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE)
- Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI)
- Transdisciplinary Research in Cancer of the Lung (TRICL)
- Breast Cancer Association Consortium (BCAC)
- Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
The OncoArray Network welcomes additional members.
Network members can gain access to the SNP list limited annotation. In joining the Network, members agree to abide by its internal data sharing policies. These data sharing policies require that groups involved in research for any of the categories that contribute to development of the OncoArray (breast, colon, lung, prostate, ovarian cancers, and carriers of BRCA1 and BRCA2 mutations) will coordinate their research and publications with existing members.
Investigators studying other diseases may also join the Network. While such groups may not be expected to share data with the Network, they will still be expected to co-ordinate publications with existing members. Learn more about the publication guidelines.
OncoArray Network Steering Committee
Current members of the OncoArray Steering Committee are:
- Stephen Gruber, M.D., Ph.D., M.P.H., University of Southern California
- Genome Canada/Genome Quebec/CIHR funded Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer international project
- Cancer Research UK
- NCI DCEG